Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Baseline incidence of adverse birth outcomes and infant influenza and pertussis hospitalisations prior to the introduction of influenza and pertussis vaccination

These baseline data are essential to assess the safety and effectiveness of influenza and pertussis vaccinations in pregnant women from the NT

Research

Severe and Complicated Varicella and Associated Genotypes 10 Years After Introduction of a One-Dose Varicella Vaccine Program

Severe hospitalized varicella still occurs with a 1-dose varicella program, although predominantly in unvaccinated children

Research

Vaccine acceptance: Science, policy, and practice in a ‘post-fact’ world

We must continue our efforts to promote vaccine acceptance and thus increase vaccination uptake, by fostering more effective vaccination communication

Research

Developmental outcomes following vaccine-proximate febrile seizures in children

To compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.

Research

Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers

One dose of MenACWY-TT boosts protection against MenC in primed children, is safe and extends protection against MenA, MenW and MenY

Research

The politics of picking: Selective vaccinators and population-level policy

Public health systems face tensions between individuals and the collective. Parents who selectively vaccinate demonstrate this tension

Research

Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients

All children who are receiving therapy for cancer should receive a single dose of PCV13 as soon as possible after diagnosis, regardless of prior PCV exposure.

Research

Development of Group A streptococcal vaccines: an unmet global health need

This review provides an update on the current status of Group A Streptococcus vaccine development, & describes global efforts to accelerate the development...

Research

4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results from a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults

Meningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2, 0-6, or 0-2-6 months, was demonstrated by endogenous complement-human serum bactericidal antibody (enc-hSBA) assay against an epidemiologically relevant panel of 110 MenB strains.

Research

Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease

Regular intramuscular (i.m.) benzathine penicillin G (BPG) injections have been the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s. Patient adherence to IM BPG is poor, largely due to pain, the need for regular injections every 3-4 weeks and health sector delivery challenges in resource-limited settings. There is an urgent need for new approaches for secondary prophylaxis, such as an implant which could provide sustained penicillin concentrations for more than 6 months.